Novartis News | finanzen.ch

Novartis Aktie VALOR 1200526 / ISIN CH0012005267

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

27.03.19	Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease (GlobeNewswire)
22.03.19	Novartis plans for Alcon spin-off on April 9, 2019 (GlobeNewswire)
18.03.19	Alcon Announces Acquisition of PowerVision, Inc. (GlobeNewswire)
14.03.19	Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy (GlobeNewswire)
14.03.19	Novartis announces change in Sandoz leadership (GlobeNewswire)
11.03.19	Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW (GlobeNewswire)
05.03.19	Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®* (GlobeNewswire)
04.03.19	Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China (GlobeNewswire)
28.02.19	Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrates gut (GlobeNewswire)
28.02.19	Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting (GlobeNewswire)
25.02.19	Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off (GlobeNewswire)
25.02.19	Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a) (GlobeNewswire)
13.02.19	Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease (GlobeNewswire)
30.01.19	Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018 (GlobeNewswire)
30.01.19	Novartis erzielt 2018 ein kräftiges Umsatzwachstum bei gleichzeitiger Steigerung der Kerngewinnmarge, baut wegweisende Therapie¬plattformen auf und fokussiert das Unternehmen (GlobeNewswire)
08.01.19	Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease (GlobeNewswire)
07.01.19	Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder (GlobeNewswire)
21.12.18	Novartis successfully completes acquisition of Endocyte (GlobeNewswire)
20.12.18	Novartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapies (GlobeNewswire)
20.12.18	Novartis announces new CEO of Oncology Business Unit (GlobeNewswire)
19.12.18	Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises (GlobeNewswire)
19.12.18	Alcon Announces Acquisition of Tear Film Innovations, Inc. (GlobeNewswire)
13.12.18	Novartis receives European Commission approval for self-administration of Xolair® across all indications (GlobeNewswire)
10.12.18	Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder (GlobeNewswire)
08.12.18	Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease (GlobeNewswire)
06.12.18	Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses (GlobeNewswire)
03.12.18	Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1 (GlobeNewswire)
02.12.18	Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies (GlobeNewswire)
01.12.18	Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers (GlobeNewswire)
01.12.18	Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program (GlobeNewswire)
29.11.18	Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe (GlobeNewswire)
27.11.18	Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim) (GlobeNewswire)
27.11.18	Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London (GlobeNewswire)
23.11.18	Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease (GlobeNewswire)
20.11.18	Novartis rises to second place in 2018 Access to Medicine Index (GlobeNewswire)
16.11.18	FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication (GlobeNewswire)
16.11.18	Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer (GlobeNewswire)
13.11.18	Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London (GlobeNewswire)
11.11.18	New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients (GlobeNewswire)
05.11.18	Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms (GlobeNewswire)
02.11.18	Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs (GlobeNewswire)
02.11.18	Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology (GlobeNewswire)
31.10.18	Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz) (GlobeNewswire)
29.10.18	Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH (GlobeNewswire)
27.10.18	Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD (GlobeNewswire)
26.10.18	Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis (GlobeNewswire)
23.10.18	Alcon to develop SMART Suite digital health platform for cataract surgery (GlobeNewswire)
23.10.18	Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed (GlobeNewswire)
22.10.18	Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma (GlobeNewswire)
20.10.18	Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone (GlobeNewswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swiss Life Hldg	812.40	0.45 %	K V
Geberit	552.80	0.36 %	K V
Swisscom	513.50	0.20 %	K V
Logitech Intl	75.48	0.13 %	K V
Givaudan	3’825.00	0.05 %	K V
Part Grp Hldg	1’246.00	-1.35 %	K V
Novartis	96.82	-1.63 %	K V
Sonova Hldg	252.10	-1.68 %	K V
Lonza Grp	532.00	-1.77 %	K V
Roche Hldg G	286.80	-1.92 %	K V

mehr

20:03		Dow Jones aktuell: Dow Jones im Plus
18:01		Pluszeichen in New York: Dow Jones mittags freundlich
17:58		Verluste in Frankfurt: MDAX präsentiert sich schlussendlich leichter
17:58		Schwacher Handel in Europa: STOXX 50 beendet den Mittwochshandel im Minus
17:58		Euro STOXX 50-Handel aktuell: Euro STOXX 50 schwächelt schlussendlich
17:58		Minuszeichen in Zürich: SPI zum Ende des Mittwochshandels im Minus
17:58		Mittwochshandel in Frankfurt: LUS-DAX beendet den Handel mit Verlusten